ACM
MLYS icon

Atika Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Atika Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-174,000
Closed -$6.6M – 101
2025
Q3 		$6.6M Buy
+174,000
New +$3.76M 0.53% 48

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Atika Capital Management's MLYS Position: Q4 2025 in Review

Atika Capital Management sold out of Mineralys Therapeutics (MLYS) in Q4 2025, closing a stake of 174,000 shares — an estimated $6.6M sold.

Atika Capital Management first reported a position in MLYS in Q3 2025 and held it in 1 quarter. The position peaked at $6.6M in Q3 2025. 223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

  • Atika Capital Management reported no remaining Mineralys Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Atika Capital Management sold 174,000 Mineralys Therapeutics shares in Q4 2025, an estimated $6.6M.
  • Atika Capital Management first reported a position in Mineralys Therapeutics in Q3 2025 and held it in 1 quarter.
  • Atika Capital Management's Mineralys Therapeutics position peaked at $6.6M in Q3 2025.
  • 223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on Atika Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.